Regarding treatment, conservative management was followed in eyes without vitreous hemorrhage, in those patients with vitreous hemorrhage grade I or at least 4 weeks of evolution, and in those eyes whose media cleared in less than 8 weeks, with intravitreal anti-VEGF according to the evolution and retinal photocoagulation in areas of non-perfusion after clearing of the media (59%), guided by fluorescein angiography, once the effect of the anti-VEGF wore off (Fig. 5). The gene discussed is VEGFA; the disease is vitreous hemorrhage.